retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide—A Game Changer in Obesity
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)









![GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions[v1]](https://www.preprints.org/frontend/picture/ms_xml/manuscript/b0714be486d8e9fe95dfcbc85df1634c/preprints-164552-g001.png)















